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Protocol
========

1. Cell Free Extract Preparation.
---------------------------------

1.  Two grams of a dry *Escherichia coli* bacterial pellet obtained from mid-log phase cultures are washed, twice, with half liter of buffer A containing 10 mM Tris-acetate, pH 8.0, 14 mM magnesium acetate, 60 mM potassium acetate, and 50 μg/ mL phenylmethanesulphonylfluoride (PMSF) by centrifugation at 5000 X g for 5 min at 4°C. After washing, the bacterial pellet is resuspended in 40 mL of buffer A.

2.  The bacterial cells are disrupted using a French Press, applying 6000 psi pressure. This pressure corresponds to 600 units using a one-inch piston. The disrupted suspension is collected in a clean glass tube (50 mL).

3.  The disrupted suspension is treated with 1 mM dithiotreitol (DTT) and is centrifuged at 30,000 x g for 30 min. The centrifugation procedure is repeated, using the resulting supernatant. The final supernatant is dispensed (1 mL) into microtubes. Finally, the aliquots are frozen using a dry ice-ethanol mixture or liquid nitrogen, and are stored at -60°C or -80°C.

2. Preparation of Cell Free Extracts Depleted of RF2.
-----------------------------------------------------

1.  4.5 mL of protein A sepharose 4B slurry beads are mixed with 5 mL of an anti-RF2 anti-serum using a rotating wheel at room temperature, for one hour. The mixture is centrifuged at 2500 x g to separate the beads from the antiserum. Upon discarding the supernatant, these beads containing the anti-RF2 antibodies (anti-RF2 beads) are later washed by resuspension in 1 mL of buffer B containing 35 mM Tris-acetate pH 7.8, 10 mM magnesium acetate, 30 mM ammonium acetate, 60 mM potassium glutamate and 5 μg/ mL of leupeptin proteinase inhibitor. The anti-RF2 beads are then separated from buffer B by centrifugation using the same conditions indicated above. The washing procedure is repeated twice.

2.  One mL of the cell-free extract is mixed with 150 μL of anti-RF2 beads using a rotating wheel, at 4°C, for two hours. The mixture is centrifuged at 10,000 x g to separate the cell-free extract from the beads. The supernatant is removed and treated again with another 150 μL of anti-RF2 beads. This procedure is repeated once more with the resulting cell-free extract solution. The final cell-free extract solution is dispensed (100 μL) into microtubes. The aliquots are frozen using a dry ice-ethanol mixture or liquid nitrogen, and are stored at -60°C or -80°C.

3. Preparation of a DNA Template.
---------------------------------

1.  Prepare a 1 mL PCR-reaction by mixing 600 femtomoles of the plasmid template containing the sequences to be translated (Fig 1), with 0.4 nanomoles of each of the oligodeoxynucleotides indicated in Fig 1, 0.2 micromoles of each dNTP and 50 U of Taq-DNA polymerase in the buffer supplied by Stratagene Co. Perform the amplification reaction under the follow conditions: 94°C for 2 min, (94°C for 30 s, 55 °C for 30 s, 72°C for 1 min; for 30 cycles) and 72°C for 12 min.

2.  Purify the PCR-products by precipitating the DNA by adding 1/10 volume of 3 M sodium acetate, pH 5.2, and 2 volumes of ice-cold ethanol. Repeat the precipitation procedure once more. Resuspend the DNA in 100 μL of diethyl-pyrocarbonate (DEPC) treated-water. Typically, this procedure yields 100 μg of a 600 bp DNA product.

3.  Verify the integrity of the PCR products by electrophoresis on agarose gels.

4. Preparation of Biotin Labeled mRNA.
--------------------------------------

1.  Prepare a 100 μL *in vitro* transcription reaction in DEPC treated water by mixing 5 μg of the PCR-generated DNA fragment with 0.5 micromoles of ATP, CTP, GTP, 0.3 micromoles of UTP, 50 nanomoles of biotin-16-UTP, and 10 μL of T7 enzyme mix in the buffer supplied by Promega Co. Incubate the reaction mixture at 37°C for 3 hours. To quantify the amount of mRNA obtained, the DNA template should be eliminated by adding RNase-free DNase. Incubate the reaction at 37°C for 10 min.

2.  Purify the mRNA products by precipitating the RNA by adding 1/10 volume of 3 M sodium acetate, pH 5.2, and 2 volumes of cold ethanol. Repeat the precipitation procedure once more. Resuspend the mRNA in 100 μL of DEPC treated-water. Usually, this procedure yields between 1-2 mg of a 600 nt biotin labeled mRNA product.

3.  Verify the integrity of the biotin labeled mRNA products by electrophoresis on agarose gels.

5. Isolation of Translating Ribosomes Containing a Peptidyl-tRNA.
-----------------------------------------------------------------

1.  Prepare 500 μL of an *in vitro* translation reaction mixture in DEPC treated water by mixing 10-15 μg of biotin-labeled mRNA with 75 nanomoles of each of the nineteen amino acids -all except the amino acid that will be replaced by a radioactive amino acid, 50 μCi of a radioactive amino acid (37MBq), and 20-50 μL of RF2-depleted cell-free extract, in a buffered reaction mixture containing 40 mM Tris-acetate, pH 8.0, 10 mM magnesium acetate, 175 mM potassium acetate, 10 mM ammonium acetate, 2 mM DTT, 2 mM ATP, 0.5 mM GTP, 30 mM phosphoenolpyruvate (PEP), 0.3 U/ mL pyruvate kinase (PK), 3.5% polyethylene glycol 8000, 1 mM spermidine, 20 μg/ mL folinic acid, and 250 μg/ mL tRNA from *E. coli*. Incubate the reaction mixture at 37°C for 10 minutes. The order of addition of the reaction components is very important. The cell-free extract must be mixed first with the buffer solution containing the amino acids and the final mixture incubated for 5 min at room temperature to allow the activation of the ribosomes. Later, the biotin-labeled mRNAs are added. For structural analyses using chemical modification procedures, the addition of a radioactive amino acid is not required.

2.  Add to the translation reaction mixture - 3 mL of streptavidin paramagnetic beads (SMB) suspended in buffer C containing 35 mM Tris-acetate, pH 8.0, 10 mM magnesium acetate, 175 mM potassium acetate, 10 mM ammonium acetate and 1 mM DTT. Incubate the new suspension at room temperature for 10 min.

3.  Separate the SMB from the mixture by applying a magnetic field (MF) using magnetic separation stands.

4.  Resuspend the SMB in buffer C and separate the beads again using the MF. Repeat this washing procedure twice. Resuspend the beads in 500 μL of buffer C, store the suspension on ice, and perform the next procedure immediately.

6. Analysis of the Isolated Ribosomes Containing the Peptidyl-tRNA.
-------------------------------------------------------------------

For peptidyl-tRNA
-----------------

1.  Mix 10 μL of the SMB (suspended in buffer C) with 10 μL of a loading buffer containing 50 mM Tris-HCl, pH 6.8, 2.5% (v/v) glycerol, 4% sodium dodecyl sulfate, 2 mM DTT and 0.2 mg/ mL bromophenol blue. Resolve the components attached to the beads by running the samples in 10% Tris-tricine polyacrylamide gels.

2.  Dry the gels using a vacuum gel-dryer.

3.  Verify the integrity and purification of the peptidyl-tRNA by exposing the dried gel to an X-ray film.

For ribosomal RNA
-----------------

1.  Add 190 μL of 2 mM ethylenediaminetetraacetate (EDTA) solution prepared with DEPC-treated water, and 200 μL of phenol equilibrated with water, to 10 μL of a bead suspension. Mix the suspension by vigorous vortexing and separate the inorganic phase from the organic phase by centrifugation at 10,000 x g for 3 min at room temperature. Collect the top water layer in a new microtube.

2.  Precipitate the RNA from the water layer by adding 1/10 volume of 3 M sodium acetate, pH 5.2, 1 μL of 20 mg/ mL of glycogen solution, and 2 volumes of ice-cold ethanol. Resuspend the RNA in 10 μL of DEPC-treated water.

3.  Verify the integrity of the ribosomal RNAs by electrophoresis on agarose gels. Usually, 50 μL of beads suspension yields 1μg of ribosomal RNA.

7. Representative Results:
--------------------------

Figure 2 presents the results of a series of analyses evaluating the quality and functionality of translating ribosomes isolated using the procedure outlined. The observation of a unique band resolved in polyacrylamide gels indicates the presence of polypeptides bound to the biotin-labeled mRNAs attached to the SMB (Figure 2A). The purification of ribosomal RNAs using this procedure establishes the presence of ribosomes bound to these biotin-labeled mRNAs, as well (Figure 2B). Addition of puromycin, an antibiotic that induces the peptidyl-transferase activity of the ribosome, results in cleavage of the nascent peptidyl-tRNAs^1^. This is observed as a shift in the migration pattern of the isolated polypeptide in polyacrylamide gels (Fig 2C). Together, these data indicate that biotin-labeled mRNAs attached to the SMB contain functional ribosomes with peptidyl-tRNAs.

The isolation of translating ribosomes containing specific peptidyl-tRNAs permits the study of the effects of peptidyl-tRNAs, antibiotics, and other molecules, on ribosome function (Figure 3A), and on ribosome structure (Figure 3B). In the examples presented here the antibiotic sparsomycin and the amino acid tryptophan (Trp) inhibit the hydrolytic cleavage of the nascent *tnaC*-tRNA peptidyl-tRNA induced by RF2 in the isolated ribosomes (Figure 3A). The interaction of sparsomycin or Trp with the ribosome also induces structural changes in some nucleotides that constitute the 23S rRNA of the translating ribosome (Fig 3B). In summary, the biological material obtained using the procedure described here are useful in obtaining additional understanding of the structural contacts involved in inhibition of ribosome function upon its interaction with various molecular factors.

**Figure 1.** Procedure used to produce and purify translating ribosomes containing peptidyl-tRNAs. DNA fragments ca. 650 bp in length, containing the *tnaC* gene and its adjacent region, shown in the figure, are used as templates in preparing mRNAs containing biotin, \[(bio)UMP\]mRNA. These DNA fragments are produced by PCR procedures using the oligodeoxynucleotides indicated at the top of the figure. Underlined letters mark the location of the T7 promoter encoded in the nucleotide primer. Bold letters indicate the Shine-Dalgarno sequence that is used in the translation of the *tnaC* mRNA sequences. The T7 promoter in the DNA fragment is recognized by T7 RNA polymerase which is used to transcribe (arrow) the *tnaC* sequence and the non-coding sequence downstream. Transcription is terminated when RNA polymerase reaches the 3\'-end of the DNA fragment, after the *rpoBC* terminator sequences (*rpoBC*\"t\"). The stem-loop structure of the *rpoBC* terminator protects the mRNA from the 3\'-5\' exoribonuclease activity present in the cell-free extracts used in the *in vitro* translation reactions. The isolated \[(bio)UMP\]mRNAs are used to generate stalled, translating ribosomes, using *in vitro* translation assays. The *tnaC* sequence in the \[(bio)UMP\]mRNA is translated by a ribosome which stalls when the last amino acid is incorporated, due to the absence of the Release Factor (RF2) from the reaction mixture. The ribosome-\[(bio)UMP\]mRNA complexes are isolated from the total reaction mixture using streptavidin-magnetic-beads (SMB) which bind the biotin-labeled nucleotides incorporated in the mRNA. The SMBs bound to the ribosome-\[(bio)UMP\]mRNA complexes are extracted from the total reaction mixture by using a magnetic field (MF).

**Figure 2.** Structural and functional analyses of the isolated complexes. A) *In vitro* translation reactions were performed with \[(bio)UMP\]mRNAs in which the start codon of the *tnaC* gene was replaced by a stop codon. The final products were isolated using streptavidin beads, as is indicated in Fig 1. Reaction products and isolated molecules were then analyzed by electrophoresis on polyacrylamide gels. The *tnaC*-tRNA and *tnaC* peptide bands are marked. B) Total RNA was isolated from the stalled complexes using phenol extraction procedures. Each isolated RNA was resolved by electrophoresis in agarose gels. Ribosomal RNAs (rRNAs) are indicated. C) Isolated complexes containing *tnaC*-tRNAs were incubated with (+) or without (-) 0.02 mM puromycin (Puro) at room temperature for 10 min. The *tnaC* peptide were labeled during translation using \[35S\]-methionine (A) or \[3H\]-proline (B).

**Figure 3.** Structural and functional analyses of ribosomes containing *tnaC*-tRNA that are bound to the antibiotic sparsomycin, or the amino acid tryptophan. A) Isolated complexes containing *tnaC*-tRNAs were incubated with (+) or without (-) sparsomycin (Spar) or tryptophan (Trp) at room temperature for 5 min. Later, the mixtures were mixed with RF2 and incubated at 37°C for 20 min. B) Analysis of methylation changes in 23S rRNA induced by molecules binding within the ribosome. Isolated complexes were pre-incubated with (+) or without (-) 2 mM Trp or Spar for 5 min at 37°C. Then, an alkylation agent, dimethyl sulfate, was added and the mixtures incubated at room temperature for an additional 20 min. Total RNA was extracted and primer extension assays were performed with a \[32P\]-labeled oligodeoxynucleotide complementary to the nucleotides of 23S rRNA which are spaced 100 nucleotides downstream from the modified nucleotide. The final products of the extension assays were resolved by electrophoresis in polyacrylamide gels. The 23S rRNA nucleotides affected by the presence of Trp or Spar are indicated.

Discussion
==========

This isolation procedure described in this report is highly reproducible. Unfortunately, the presence of short peptidyl-tRNAs produced from the same translated sequences cannot be conveniently avoided; such peptidyl-tRNAs may correspond to 15-20 % of the total isolated material (Figure 2C). These contaminants may increase in concentration when higher concentrations of biotin-labeled mRNA have been used or when the cell-free extracts used are old or have been re-used several times. Therefore, it is very important to control the quality and concentration of the components of the *in vitro* translation reactions. Alternatively, commercial high efficiency reconstituted cell-free extracts are available that can be used for the same purposes (PURE system)^18^.

Using this method, biotin-16-UMP is randomly incorporated along the length of the target mRNA. There is a possibility that some ORFs containing uridine tracts may have incorporated this modified nucleotide in their sequences, affecting their translation. Variable relative concentrations of biotin-16-UTP/UTP have to be tested during synthesis of the mRNA in order to obtain the most efficient translation. Alternative methods of biotin labeling can be used, targeting the 5\'-end, the most stable end of the mRNAs. (i) Biotin can be attached to the 5\'-end of the mRNA using 3\'-NH2ATP (3\'-amino, 3\'-deoxyadenosine triphosphate) and T4 RNA ligase^19^. (ii) 5\'-end biotin-labeled oligonucleotide can be attached to the 5\'-end of the mRNA using T4 RNA ligase as well^20^. (iii) 3\'-end biotin-labeled oligodeoxynucleotides which correspond to the complementary sequence at the 5\'-end of the mRNA could also be used to isolate the translating complexes. These biotin labeled oligodeoxynucleotides could be attached to the SMB prior to isolation. Later the SMB attached to the biotin-labeled oligodeoxynucleotides could be mixed with the translation reaction mixture to allow interaction with their complementary mRNA sequences. After isolation, the hybrid RNA-DNA region - and the region hybridizing between the biotin-labeled oligodeoxynucleotide and the mRNA sequence - could be degraded using RNAse H, separating the stalled complexes from the streptavidin beads. This alternative method may allow the complexes to be employed in future structural analyses using higher resolution methods.
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